Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 3/20 | 0.57 |
| ▸ | GSK3B | P49841 | 11/20 | 0.53 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.53 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355385 | 0.81 | L3MBTL1 (0.52) | PIK3C3TYK2JAK2JAK1 | |
| SCHEMBL3106680 | 0.81 | RAB9A (0.42) | PIK3C3MAPT | |
| SCHEMBL10352589 | 0.80 | ACVRL1 (0.61) | ACVRL1GSK3BPIK3C3MAPT | |
| SCHEMBL622391 | 0.78 | JAK2 (0.49) | PIK3C3TYK2JAK2JAK1 | |
| SCHEMBL15542541 | 0.78 | ACVRL1 (0.63) | ACVRL1GSK3BPIK3C3TYK2JAK2 | |
| SCHEMBL27873522 | 0.78 | ACVRL1 (0.63) | ACVRL1GSK3BPIK3C3TYK2JAK2 | |
| SCHEMBL16711012 | 0.77 | TYK2 (0.65) | ACVRL1GSK3BPIK3C3TYK2JAK2 | |
| SCHEMBL17539612 | 0.76 | ACVRL1 (0.62) | ACVRL1GSK3BPIK3C3TYK2JAK2 | |
| SCHEMBL22659338 | 0.76 | ACVRL1 (0.66) | ACVRL1GSK3BPIK3C3TYK2JAK2 | |
| SCHEMBL21963566 | 0.76 | ACVRL1 (0.61) | ACVRL1GSK3BPIK3C3TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8796314-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | ACVRL1 1642/4885GSK3B 80/4885PIK3C3 61/4885 |
| US-20100256172-A1 | Heteroaryls and uses thereof | PIK3R3, PIK3R1, AKT3 | ACVRL1 1340/4885GSK3B 23/4885PIK3C3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.